Dose-related Effects of Resveratrol in Different Models of Pulmonary Arterial Hypertension: A Systematic Review

Dose-related Effects of Resveratrol in Different Models of Pulmonary Arterial Hypertension: A Systematic Review

Background: Pulmonary Arterial Hypertension (PAH) is a severe and progressive disease of pulmonary arterioles. This pathology is characterized by elevation of the pulmonary vascular resistance and pulmonary arterial pressure, leading to right heart failure and death. Studies have demonstrated that r...

Full description

Saved in:
Bibliographic Details
Published in:Current cardiology reviews Vol. 16; no. 3; pp. 231 - 240
Main Authors: Ferreira, Andressa C., Serejo, Jerdianny S., Durans, Rafael, Pereira Costa, Jadna M., Maciel, Antonio W.S., Vieira, Adeilson S.M., Dias-Filho, Carlos A. A., Dias, Carlos J., Bomfim, Maria R.Q., Mostarda, Cristiano T., Brito-Monzani, Janaina de O.
Format: Journal Article
Language:English
Published: Sharjah Bentham Science Publishers Ltd 01-01-2020
Benham Science Publishers
Bentham Science Publishers
Subjects:
Animal models
Antioxidants
Apoptosis
Arterioles
Blood pressure
Congestive heart failure
Hypertension
Hypoxia
Inflammation
Interferon
Lung diseases
Monocrotaline
Pulmonary hypertension
Resveratrol
Reviews
Search engines
Systematic review
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Pulmonary Arterial Hypertension (PAH) is a severe and progressive disease of pulmonary arterioles. This pathology is characterized by elevation of the pulmonary vascular resistance and pulmonary arterial pressure, leading to right heart failure and death. Studies have demonstrated that resveratrol possesses a protective effect on the mechanisms related to the genesis of the PAH-induced by different models. Objective: This study aimed to investigate the dose-related effects of resveratrol in different models of pulmonary arterial hypertension. Methods: To identify eligible papers, we performed a systematic literature search on Scielo, Pub- Med, and Scholar Google. The research was limited to articles written in English in the last 10 years. We used the following descriptors to search: Pulmonary Arterial Hypertension and Resveratrol, OR Resveratrol, and Animal models of Pulmonary Arterial Hypertension, OR Resveratrol, and in vitro models of Pulmonary Arterial Hypertension. Results: 1724 studies were identified through the descriptors used, fifty-five studies with different models of pulmonary arterial hypertension were selected for the full review, forty-four were excluded after application of exclusion and inclusion criteria, totalizing eleven studies included in this systematic review. Conclusion: The results showed that resveratrol, at low and high doses, protects in a dosedependent manner against the development of PAH induced through monocrotaline, normoxia and hypoxia models. In addition to having chemopreventive, anti-inflammatory, antioxidant and antiproliferative properties. In the case of PAH-related myocardial injury, resveratrol protects cells from apoptosis, thus working as an antiapoptotic agent.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ISSN:1573-403X
1875-6557
DOI:10.2174/1573403X15666191203110554